Although SGLT2i medication and accompanying insulin reduction might cause muscle mass loss, there is, in comparison, limited evidence of skeletal muscle mass changes during SGLT2i medication in type 1 diabetes. This evidence concerns the gene INS and type 1 diabetes mellitus.